Sionna Therapeutics Inc. Common Stock (SION)

About SION

Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loo…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

59

Website

www.sionnatx.com

Fundamentals

1-day range

$6.15$6.65

Market cap

$2.24B

P/E (trailing)

—

P/E (forward)

-2.55

EPS (trailing)

$-2.15

Dividend yield

—

Beta

—

Avg. volume

1.61M

Forecasts

5 analyst ratings

Sionna Therapeutics Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SION

  Sionna Therapeutics Inc. Common Stock

  $5.87

  ▼ 3.14%
  Market cap $2.24BP/E —
  $4.01$54.97
• MLYS

  Mineralys Therapeutics Inc. Common Stock

  $25.59

  ▼ 1.61%
  Market cap $2.23BP/E —
  $14.94$47.65
• URGN

  UroGen Pharma Ltd. Ordinary Shares

  $43.61

  ▼ 4.15%
  Market cap $2.22BP/E —
  $15.86$50.81
• VERA

  Vera Therapeutics Inc. Class A Common Stock

  $34.19

  ▼ 1.18%
  Market cap $2.30BP/E —
  $21.2$56.05
• SLS

  SELLAS Life Sciences Group Inc. Common Stock

  $13.17

  ▼ 13.45%
  Market cap $2.18BP/E —
• BHVN

  Biohaven Ltd. Common Shares

  $15.42

  ▼ 4.37%
  Market cap $2.17BP/E —
  $7.48$18.57
• VRDN

  Viridian Therapeutics Inc. Common Stock

  $23.09

  ▼ 3.31%
  Market cap $2.32BP/E —
  $13.18$34.29

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• These stocks have an unusual volume in today's session
  ChartMill · 8/13/2026
• 12 Health Care Stocks Moving In Wednesday's Intraday Session
  Benzinga · 8/12/2026
• Sionna's SION-719 Failure Changes Everything (Rating Downgrade)
  SeekingAlpha · 8/12/2026
• Guggenheim Downgrades Sionna Therapeutics to Neutral
  Benzinga · 8/11/2026
• Wedbush Downgrades Sionna Therapeutics to Neutral, Lowers Price Target to $5
  Benzinga · 8/11/2026
• Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks
  Benzinga · 8/10/2026
• 12 Health Care Stocks Moving In Monday's Intraday Session
  Benzinga · 8/10/2026
• Crude Oil Surges 3%; Sionna Therapeutics Shares Plunge
  Benzinga · 8/10/2026

• Peter A. Thompson · July 7, 2026 · Sale

  85.9K @ $44.86
• ORBIMED ADVISORS LLC · July 7, 2026 · Sale

  85.9K @ $44.86
• Jennifer Fitzpatrick · July 6, 2026 · Option Exercise

  10.3K @ $6.11
• Jennifer Fitzpatrick · July 6, 2026 · Sale

  10.3K @ $43.6
• Peter A. Thompson · June 30, 2026 · Sale

  115.8K @ $45.5
• ORBIMED ADVISORS LLC · June 30, 2026 · Sale

  115.8K @ $45.5
• Stelzer Laurie · June 17, 2026 · Grant

  17.3K
• Bruce Booth · June 17, 2026 · Grant

  17.3K
• Paul J. Clancy · June 17, 2026 · Grant

  17.3K
• Peter A. Thompson · June 17, 2026 · Grant

  17.3K
• RA Capital Healthcare Fund LP · June 17, 2026 · Grant

  17.3K
• Peter A. Thompson · May 27, 2026 · Sale

  101 @ $44.49
• ORBIMED ADVISORS LLC · May 27, 2026 · Sale

  101 @ $44.49
• Peter A. Thompson · May 11, 2026 · Sale

  184.6K @ $46.22
• ORBIMED ADVISORS LLC · May 11, 2026 · Sale

  184.6K @ $46.22

Institutional Ownership

March 31, 2026

Total shares held

43.67M

Total value held

$1.72B

Institutional holders

117